Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
New antiretroviral drugs and approaches to HIV treatment.
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
RNA interference of HIV replication.
Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Preferential attachment of HIV particles to activated and CD45RO+CD4+ T cells.
Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals.
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.